XHKG3759
Market cap13bUSD
Dec 20, Last price
13.72HKD
1D
-0.15%
1Q
23.16%
IPO
-26.94%
Name
Pharmaron Beijing Co Ltd
Chart & Performance
Profile
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 11,537,996 12.39% | 10,266,288 37.92% | 7,443,770 45.00% | |||||||
Cost of revenue | 8,866,701 | 7,749,700 | 5,327,068 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 2,671,295 | 2,516,588 | 2,116,702 | |||||||
NOPBT Margin | 23.15% | 24.51% | 28.44% | |||||||
Operating Taxes | 256,106 | 314,254 | 290,919 | |||||||
Tax Rate | 9.59% | 12.49% | 13.74% | |||||||
NOPAT | 2,415,189 | 2,202,334 | 1,825,783 | |||||||
Net income | 1,601,096 16.48% | 1,374,604 -17.24% | 1,661,029 41.68% | |||||||
Dividends | (444,792) | (404,761) | (284,715) | |||||||
Dividend yield | 0.86% | 0.75% | 0.44% | |||||||
Proceeds from repurchase of equity | (830) | (1) | ||||||||
BB yield | 0.00% | 0.00% | ||||||||
Debt | ||||||||||
Debt current | 577,071 | 901,747 | 577,593 | |||||||
Long-term debt | 9,370,060 | 5,975,290 | 4,991,860 | |||||||
Deferred revenue | 152,375 | 149,439 | ||||||||
Other long-term liabilities | 799,328 | 112,093 | 81,559 | |||||||
Net debt | 2,843,882 | 4,371,241 | 471,013 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,753,539 | 2,142,816 | 2,058,044 | |||||||
CAPEX | (2,865,321) | |||||||||
Cash from investing activities | (2,250,833) | |||||||||
Cash from financing activities | 3,915,262 | 3,661,395 | ||||||||
FCF | 697,679 | (557,902) | (1,007,206) | |||||||
Balance | ||||||||||
Cash | 6,720,255 | 2,242,846 | 5,098,441 | |||||||
Long term investments | 382,994 | 262,950 | ||||||||
Excess cash | 6,526,350 | 1,992,482 | 4,726,252 | |||||||
Stockholders' equity | 7,673,156 | 5,832,119 | 4,256,172 | |||||||
Invested Capital | 16,872,959 | 15,040,089 | 11,441,058 | |||||||
ROIC | 15.14% | 16.63% | 19.33% | |||||||
ROCE | 11.42% | 14.55% | 13.34% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,775,248 | 1,184,187 | 1,213,227 | |||||||
Price | 28.98 -36.07% | 45.33 -15.22% | 53.47 -55.59% | |||||||
Market cap | 51,446,683 -4.16% | 53,679,195 -17.25% | 64,871,227 -54.71% | |||||||
EV | 54,971,813 | 58,341,688 | 65,508,306 | |||||||
EBITDA | 3,598,466 | 3,212,768 | 2,614,622 | |||||||
EV/EBITDA | 15.28 | 18.16 | 25.05 | |||||||
Interest | 182,192 | 167,312 | 83,073 | |||||||
Interest/NOPBT | 6.82% | 6.65% | 3.92% |